menu
    • menu
    [{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"AAZ","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Delix Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Delix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Delix Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"ARTIS Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2021","type":"Series A Financing","leadProduct":"DLX-1","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Delix Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Delix Therapeutics \/ ARTIS Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Delix Therapeutics \/ ARTIS Ventures"},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Partnership","leadProduct":"DLX-7","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Delix Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Delix Therapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"4","companyTruncated":"Delix Therapeutics \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"Cellectricon","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Delix Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Delix Therapeutics \/ Delix Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Delix Therapeutics \/ Delix Therapeutics"},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"DLX-001","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Delix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Delix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Delix Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"DLX-001","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Delix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Delix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Delix Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"DLX-007","moa":"","graph1":"Psychiatry\/Psychology","graph2":"IND Enabling","graph3":"Delix Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Delix Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"5","companyTruncated":"Delix Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"DLX-001","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Delix Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Delix Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Delix Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Delix Therapeutics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Neuroplastogen","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Discovery","graph3":"Delix Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"","sponsorNew":"Delix Therapeutics \/ U.S. Department of Defense","highestDevelopmentStatusID":"2","companyTruncated":"Delix Therapeutics \/ U.S. Department of Defense"}]

    Find Clinical Drug Pipeline Developments & Deals by Delix Therapeutics

    Menu

    Delix Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Delix Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Delix Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neuroplastogen

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Discovery

                            Sponsor : U.S. Department of Defense

                            Deal Size : $0.8 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Delix Awarded Grant from US Department of Defense for Neuroplastogen to Treat Hearing Loss

                            Details : The financing will support the advancement of a neuroplastogen, a novel, first-in-class, non-toxic, that has been found to repair cochlear synaptopathy that contribute to hidden hearing loss.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 04, 2024

                            Lead Product(s) : Neuroplastogen

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Discovery

                            Sponsor : U.S. Department of Defense

                            Deal Size : $0.8 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Delix Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Delix Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DLX-001

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Delix Reports DLX-001 Shows CNS Penetration Without Psychotomimetic Effects

                            Details : DLX-001 is the first of several psychoplastogens promoting rapid neuroplasticity without hallucinatory responses, being investigated for major depressive disorder (MDD).

                            Brand Name : DLX-001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 13, 2024

                            Lead Product(s) : DLX-001

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Delix Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Delix Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DLX-007

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : IND Enabling

                            Sponsor : National Institutes of Health

                            Deal Size : $0.3 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Delix Therapeutics Awarded National Institutes of Health Grant to Advance Vital Research of Novel Neuroplastog...

                            Details : The grant will support further development of novel neuroplastogen and ibogaine analog, DLX-007, a novel, first-in-class, neuroplastogen being evaluated in a range of substance use disorders (SUDs), including opioid and stimulant use.

                            Brand Name : DLX-007

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 13, 2023

                            Lead Product(s) : DLX-007

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : IND Enabling

                            Sponsor : National Institutes of Health

                            Deal Size : $0.3 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Delix Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Delix Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DLX-001

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Delix Therapeutics Announces Completion of 1st Cohort Dosing, Dose Escalation Approval in Phase I Trial for No...

                            Details : DLX-001 is the first of several psychoplastogens to be approved for human trials. It promotes rapid and enduring neuroplasticity, matching or exceeding the efficacy of natural psychedelic compounds, without hallucinatory responses even at high doses.

                            Brand Name : DLX-001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 20, 2023

                            Lead Product(s) : DLX-001

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Delix Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Delix Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DLX-001

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Delix Therapeutics Initiates Phase I Trial for Novel Compound DLX-001

                            Details : DLX-001 is the first of several psychoplastogens to be approved for human trials. It promotes rapid and enduring neuroplasticity, matching or exceeding the efficacy of natural psychedelic compounds, without hallucinatory responses even at high doses.

                            Brand Name : DLX-001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 09, 2023

                            Lead Product(s) : DLX-001

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Delix Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Delix Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Recipient : Cellectricon

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Delix Therapeutics Partners With Cellectricon, Expressive Neuroscience and Expands Science Team To Accelerate ...

                            Details : Delix have partnered with Cellectricon to create novel assays to measure the structural and functional plasticity effects of Delix's psychoplastogen compounds using cutting-edge technologies.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 14, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Recipient : Cellectricon

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Delix Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Delix Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DLX-7

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : National Institute on Drug Abuse

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Delix Therapeutics Partners with the National Institute on Drug Abuse (NIDA) to Advance Research on Non-Halluc...

                            Details : Under the partnership, The National Institute on Drug Abuse (NIDA) will test one of Delix's lead clinical candidates DLX-7, non-hallucinogenic and non-toxic ibogaine analog, for use in treating a range of substance use disorders.

                            Brand Name : DLX-7

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 07, 2021

                            Lead Product(s) : DLX-7

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : National Institute on Drug Abuse

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Delix Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Delix Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DLX-1

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : ARTIS Ventures

                            Deal Size : $70.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Delix Therapeutics Closes $70 Million Series A Financing to Advance Pipeline of Novel Psychoplastogen Therapeu...

                            Details : The Company expects to use the proceeds to advance two lead candidates through Phase 1 clinical trials, DLX-1 and DLX-7, which are currently undergoing pre-IND safety and toxicology studies to enable clinical trials.

                            Brand Name : DLX-1

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 27, 2021

                            Lead Product(s) : DLX-1

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : ARTIS Ventures

                            Deal Size : $70.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Delix Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Delix Therapeutics

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AAZ

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Delix Therapeutics Publishes Study Demonstrating Therapeutic Potential for a Psychedelic Analog--Without Hallu...

                            Details : The paper reveals DLX-1—a new compound inspired by the chemical structures of common psychedelic substances that demonstrates sustained antidepressant effects but without hallucinogenic properties.

                            Brand Name : DLX-1

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 28, 2021

                            Lead Product(s) : AAZ

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth